NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
4/8 — Partial
Drug data last refreshed 15h ago · AI intelligence enriched 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHOPRESSA (netarsudil) is a topical ophthalmic solution approved in December 2017 for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a Rho kinase inhibitor that works by increasing conventional and uveoscleral outflow of aqueous humor. The drug represents a novel mechanism of action in the glaucoma treatment armamentarium.
$175MPart D
Peak7.5 years to LOEThe product is in peak commercial phase with substantial Part D spending ($175M in 2023), indicating strong market penetration and ongoing commercial team investment and market defense activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Started Jul 2026
50 enrolled
Ocular HypertensionSuspect Glaucoma
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Started Jun 2026
50 enrolled
GlaucomaOcular Hypertension
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Started Jun 2025
70 enrolled
Primary Open Angle Glaucoma or Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Started Aug 2024
Worked on RHOPRESSA at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.